Mediterr J Rheumatol 2020;31(4):433-5
Hydroxychloroquine and QT Prolongation in Older Patients with Rheumatic Diseases: Who is afraid of the Boogeyman? We are not!
Authors Information

1. Azienda Sanitaria Provinciale Catanzaro, Geriatric Medicine department - Fragility Outpatient Clinic, Casa della Salute Chiaravalle Centrale, Catanzaro, Italy

2. Azienda Ospedaliera Pugliese-Ciaccio di Catanzaro, Geriatric Unit, General Hospital, Catanzaro, Italy

3. Azienda Sanitaria Locale Napoli 3 sud, Internal and Geriatric Medicine department – Geronthorheumatological Outpatient Clinic, poliambulatorio “Mariano Lauro”, Sant’Agnello, Naples, Italy

Alberto Castagna, Ciro Manzo 

  1. Manzo C. The role of hydroxychroloquine sulphate in the geriatric patient with coronavirus disease 2019 (COVID-19). What is useful to know for the geriatrician? Geriatric Care 2020;6:25-8.
  2. Coronavirus Disease (COVID-19) events as they happen. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-theyhappen. Accessed July 4, 2020.
  3. Bogdanos DP, Daniil Z, Zakynthinos E, Gourgoulianis K, Sakkas LI. When there is a pandemic there is no time to waste: should we have hydroxychloroquine in our armoury against COVID-19 infected patients? Mediterr J Rheumatol 2020;31:94-7.
  4.  Chorin E, Dai M, Shulman E, Wadhwani L, Bar-Cohen R, Barbhaiya C, et al. The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin. Nat Med 2020 Jun;26(6):808-09.
  5. Mercuro NJ, Yen CF, Shim DJ, Maher TR, McCoy CM, Zimetbaum PJ, et al. Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19). JAMA Cardiol 2020 Sep 1;5(9):1036-41.  
  6. Passman R, Kadish A. Polymorphic ventricular tachycardia, long Q-T syndrome, and torsades de pointes. Medical Clinics of North America. 2001;85:321–341. doi: 10.1016/s0025-7125(05)70318-7.
  7. World Health Organization. Malaria policy advisory committee meeting: the cardiotoxicity of antimalarials; 22 March, 2017, pp. 6-7. Available from: http://www.who.int
  8. Chatre C, Roubille F, Vernhet H, Jorgensen C, Pers YM. Cardiac complications attributed to chloroquine and hydroxychloroquine: a systematic review of the literature. Drug Saf 2018;41:919-31.
  9. Capel R, Herring N, Kalla M, Yavari A, Mirams GR, Douglas G, et al. Hydroxychloroquine reduces heart rate by modulating the hyperpolarization-activated current if: novel electrophysiological insights and therapeutic potential. Heart Rhythm 2015;12:2186-94.
  10. Michishita R, Fukae C, Mihara R, Ikenaga M, Morimura K, Takeda N, et al. Association between the physical activity and heart rate corrected-QT interval in older adults. Geriatr Gerontol Int 2015;15:895-901.
  11. Tisdale JE, Jayes HA, Kingery JR, Mourad NA, Trujillo TN, Overholser BR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes 2013;6:479-487.